Intrinsic Medicine Terminates $178.8M SPAC Deal With Phoenix Biotech Amid Market Downturn
Seattle biotech startup Intrinsic Medicine's planned $178.8 million SPAC merger with Phoenix Biotech Acquisition Corp. has been terminated due to market conditions. The company had previously withdrawn its traditional IPO filing and plans to advance clinical trials for its sugar-based therapeutic molecules.
No comments yet.